{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:05:30Z","timestamp":1793502330243,"version":"4.5.0"},"reference-count":195,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41568-024-00788-2","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T16:02:51Z","timestamp":1740067371000},"page":"293-315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Defining a \u2018cells to society\u2019 research framework for appendiceal tumours"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8001-8793","authenticated-orcid":false,"given":"Andreana N.","family":"Holowatyj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Overman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos I.","family":"Votanopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Lowy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K.","family":"Washington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-0612","authenticated-orcid":false,"given":"Cathy","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Chin","family":"Foo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojgan","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0911-4461","authenticated-orcid":false,"given":"Kamran","family":"Idrees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardaman","family":"Shergill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C.","family":"Zachos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of Appendix Cancer Pseudomyxoma Peritonei (ACPMP) Research Foundation","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"788_CR1","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00384-007-0304-0","volume":"22","author":"ME O\u2019Donnell","year":"2007","unstructured":"O\u2019Donnell, M. E., Badger, S. A., Beattie, G. C., Carson, J. & Garstin, W. I. Malignant neoplasms of the appendix. Int. J. Colorectal Dis. 22, 1239\u20131248 (2007).","journal-title":"Int. J. Colorectal Dis."},{"key":"788_CR2","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/cncr.32793","volume":"126","author":"H Singh","year":"2020","unstructured":"Singh, H., Koomson, A. S., Decker, K. M., Park, J. & Demers, A. A. Continued increasing incidence of malignant appendiceal tumors in Canada and the United States: a population-based study. Cancer 126, 2206\u20132216 (2020).","journal-title":"Cancer"},{"key":"788_CR3","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s11605-014-2726-7","volume":"19","author":"S Marmor","year":"2015","unstructured":"Marmor, S., Portschy, P. R., Tuttle, T. M. & Virnig, B. A. The rise in appendiceal cancer incidence: 2000-2009. J. Gastrointest. Surg. 19, 743\u2013750 (2015).","journal-title":"J. Gastrointest. Surg."},{"key":"788_CR4","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s11605-008-0774-6","volume":"13","author":"AN Trivedi","year":"2009","unstructured":"Trivedi, A. N., Levine, E. A. & Mishra, G. Adenocarcinoma of the appendix is rarely detected by colonoscopy. J. Gastrointest. Surg. 13, 668\u2013675 (2009).","journal-title":"J. Gastrointest. Surg."},{"key":"788_CR5","volume":"16","author":"JO Soto Llanes","year":"2024","unstructured":"Soto Llanes, J. O., Dosal Limon, S. K., Iberri Jaime, A. J., Zambrano Lara, M. & Jimenez Bobadilla, B. Lower gastrointestinal bleeding secondary to appendiceal mucinous neoplasm: a report of two cases and a review of the literature. Cureus 16, e52908 (2024).","journal-title":"Cureus"},{"key":"788_CR6","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1097\/MS9.0000000000001973","volume":"86","author":"M Xie","year":"2024","unstructured":"Xie, M. & Li, F. Incidental diagnosis of primary appendiceal signet-ring cell adenocarcinoma after appendectomy for acute appendicitis: a case report. Ann. Med. Surg. 86, 3117\u20133122 (2024).","journal-title":"Ann. Med. Surg."},{"key":"788_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.soc.2018.02.007","volume":"27","author":"KI Votanopoulos","year":"2018","unstructured":"Votanopoulos, K. I., Shen, P., Skardal, A. & Levine, E. A. Peritoneal metastases from appendiceal cancer. Surg. Oncol. Clin. N. Am. 27, 551\u2013561 (2018).","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"788_CR8","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3322\/caac.21806","volume":"73","author":"LM Janczewski","year":"2023","unstructured":"Janczewski, L. M. et al. Survival outcomes used to validate version 9 of the American Joint Committee on Cancer staging system for appendiceal cancer. CA Cancer J. Clin. 73, 590\u2013596 (2023). This article highlights key clinical components of the published version 9 of the AJCC staging system for appendiceal tumours.","journal-title":"CA Cancer J. Clin."},{"key":"788_CR9","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1053\/j.gastro.2020.06.011","volume":"159","author":"AN Holowatyj","year":"2020","unstructured":"Holowatyj, A. N. et al. Early-onset appendiceal cancer survival by race or ethnicity in the United States. Gastroenterology 159, 1605\u20131608 (2020).","journal-title":"Gastroenterology"},{"key":"788_CR10","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1158\/1055-9965.EPI-20-1505","volume":"30","author":"T Gibbs","year":"2021","unstructured":"Gibbs, T. et al. Histologic and racial\/ethnic patterns of appendiceal cancer among young patients. Cancer Epidemiol. Biomark. Prev. 30, 1149\u20131155 (2021). This population-based cohort study defines appendiceal tumour features among young patients, including the discovery that approximately one in every three adult patients is diagnosed with early-onset disease (before the age of 50 years).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"788_CR11","unstructured":"Chauhan, A. et al. AJCC Cancer Staging System: Neuroendocrine Tumors of the Appendix (American College of Surgeons, 2023)."},{"key":"788_CR12","unstructured":"National Comprehensive Cancer Network. NCCN guidelines: neuroendocrine and adrenal tumors. NCCN https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1448 (2024)."},{"key":"788_CR13","first-page":"655","volume":"38","author":"SS McMillan","year":"2016","unstructured":"McMillan, S. S., King, M. & Tully, M. P. How to use the nominal group and Delphi techniques. Int. J. Clin. Pharm. 38, 655\u2013662 (2016).","journal-title":"Int. J. Clin. Pharm."},{"key":"788_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179216","volume":"12","author":"MA Valasek","year":"2017","unstructured":"Valasek, M. A. et al. Overinterpretation is common in pathological diagnosis of appendix cancer during patient referral for oncologic care. PLoS ONE 12, e0179216 (2017). This study reveals a 28.3% overall discordance in the pathological classification of appendiceal tumours (inclusive of LAMNs and adenocarcinomas) between the originating, outside pathology group and the in-house pathology review at a single large academic medical centre, highlighting the critical need for expert pathology review of appendix tumours among all patients.","journal-title":"PLoS ONE"},{"key":"788_CR15","unstructured":"Overman, M. J. et al. AJCC Cancer Staging System: Appendix (American College of Surgeons, 2023)."},{"key":"788_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.anndiagpath.2017.11.001","volume":"32","author":"C Maedler","year":"2018","unstructured":"Maedler, C. et al. Goblet cell carcinoid of the appendix \u2014 an interobserver variability study using two proposed classification systems. Ann. Diagn. Pathol. 32, 51\u201355 (2018).","journal-title":"Ann. Diagn. Pathol."},{"key":"788_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"Nagtegaal, I. D. et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 76, 182\u2013188 (2020). The fifth edition of the WHO classification of tumours of the digestive system reflects the change in classification from goblet cell carcinoid or carcinoma to goblet cell adenocarcinoma of the appendix, given that the recognition of this tumour type has a minor neuroendocrine component.","journal-title":"Histopathology"},{"key":"788_CR18","unstructured":"National Cancer Institute, Surveillance, Epidemiology, and End Results Program. US county population data (1969\u20132022). SEER www.seer.cancer.gov\/popdata (2024)."},{"key":"788_CR19","doi-asserted-by":"publisher","first-page":"6976","DOI":"10.1245\/s10434-023-14076-0","volume":"30","author":"LD Miller","year":"2023","unstructured":"Miller, L. D. & Votanopoulos, K. I. Exploring the relationship: low-grade appendiceal mucinous neoplasms (LAMN) and mucinous adenocarcinoma as phases of the same disease spectrum. Ann. Surg. Oncol. 30, 6976\u20136977 (2023).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR20","doi-asserted-by":"publisher","unstructured":"PSM Appendiceal Tumor Writing Group, PSM Consortium Group & Turaga, K. K. Consensus guideline for the management of patients with appendiceal tumors: part 1: appendiceal tumors with peritoneal involvement. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2024.04.09.24305468 (2024).","DOI":"10.1101\/2024.04.09.24305468"},{"key":"788_CR21","doi-asserted-by":"publisher","unstructured":"PSM Appendiceal Tumor Writing Group, PSM Consortium Group & Turaga, K. K. Consensus guideline for the management of patients with appendiceal tumors: part 2: appendiceal tumors without peritoneal involvement. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2024.08.30.24309032 (2024).","DOI":"10.1101\/2024.08.30.24309032"},{"key":"788_CR22","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1097\/SLA.0b013e318269d680","volume":"257","author":"MJ Overman","year":"2013","unstructured":"Overman, M. J. et al. Improving the AJCC\/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade. Ann. Surg. 257, 1072\u20131078 (2013).","journal-title":"Ann. Surg."},{"key":"788_CR23","doi-asserted-by":"publisher","first-page":"5743","DOI":"10.1245\/s10434-023-13697-9","volume":"30","author":"G SenthilKumar","year":"2023","unstructured":"SenthilKumar, G. et al. Validation of the AJCC 8th edition staging system for disseminated appendiceal cancer patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a multi-institutional analysis. Ann. Surg. Oncol. 30, 5743\u20135753 (2023).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR24","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/modpathol.2014.37","volume":"27","author":"JM Davison","year":"2014","unstructured":"Davison, J. M. et al. Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade. Mod. Pathol. 27, 1521\u20131539 (2014).","journal-title":"Mod. Pathol."},{"key":"788_CR25","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/01.pas.0000202039.74837.7d","volume":"30","author":"RF Bradley","year":"2006","unstructured":"Bradley, R. F., Stewart, J. H. T., Russell, G. B., Levine, E. A. & Geisinger, K. R. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am. J. Surg. Pathol. 30, 551\u2013559 (2006).","journal-title":"Am. J. Surg. Pathol."},{"key":"788_CR26","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1097\/00000478-199512000-00006","volume":"19","author":"BM Ronnett","year":"1995","unstructured":"Ronnett, B. M. et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to \u201cpseudomyxoma peritonei\u201d. Am. J. Surg. Pathol. 19, 1390\u20131408 (1995).","journal-title":"Am. J. Surg. Pathol."},{"key":"788_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/PAS.0000000000000535","volume":"40","author":"NJ Carr","year":"2016","unstructured":"Carr, N. J. et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified Delphi process. Am. J. Surg. Pathol. 40, 14\u201326 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"788_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/gm559","volume":"6","author":"H Alakus","year":"2014","unstructured":"Alakus, H. et al. Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. Genome Med. 6, 43 (2014).","journal-title":"Genome Med."},{"key":"788_CR29","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41416-020-1015-3","volume":"123","author":"K Raghav","year":"2020","unstructured":"Raghav, K. et al. Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. Br. J. Cancer 123, 1262\u20131270 (2020).","journal-title":"Br. J. Cancer"},{"key":"788_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00302","volume":"2","author":"CS Ang","year":"2018","unstructured":"Ang, C. S. et al. Genomic landscape of appendiceal neoplasms. JCO Precis. Oncol. 2, 1\u201318 (2018).","journal-title":"JCO Precis. Oncol."},{"key":"788_CR31","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1158\/1078-0432.CCR-18-3388","volume":"25","author":"R Tokunaga","year":"2019","unstructured":"Tokunaga, R. et al. Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer. Clin. Cancer Res. 25, 3096\u20133103 (2019). This study analyses next-generation sequencing data from a commercial laboratory of appendiceal adenocarcinomas and right-sided and left-sided colorectal tumours, highlighting molecular differences between the two tumour types, going some way towards improving personalized treatment strategies for this rare tumour type.","journal-title":"Clin. Cancer Res."},{"key":"788_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jamcollsurg.2011.12.028","volume":"214","author":"EA Levine","year":"2012","unstructured":"Levine, E. A. et al. Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. J. Am. Coll. Surg. 214, 599\u2013606 (2012).\u00a0","journal-title":"J. Am. Coll. Surg."},{"key":"788_CR33","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/jso.27203","volume":"127","author":"RB Morgan","year":"2023","unstructured":"Morgan, R. B. et al. Mutational profiles and prognostic impact in colorectal and high-grade appendiceal adenocarcinoma with peritoneal metastases. J. Surg. Oncol. 127, 831\u2013840 (2023).","journal-title":"J. Surg. Oncol."},{"key":"788_CR34","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1373\/clinchem.2014.225565","volume":"60","author":"X Liu","year":"2014","unstructured":"Liu, X. et al. Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations. Clin. Chem. 60, 1004\u20131011 (2014).","journal-title":"Clin. Chem."},{"key":"788_CR35","doi-asserted-by":"publisher","first-page":"164","DOI":"10.21037\/jgo.2017.01.14","volume":"8","author":"E Borazanci","year":"2017","unstructured":"Borazanci, E. et al. Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. J. Gastrointest. Oncol. 8, 164\u2013172 (2017).","journal-title":"J. Gastrointest. Oncol."},{"key":"788_CR36","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/modpathol.3880572","volume":"15","author":"W Kabbani","year":"2002","unstructured":"Kabbani, W., Houlihan, P. S., Luthra, R., Hamilton, S. R. & Rashid, A. Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathological features but similar genetic alterations. Mod. Pathol. 15, 599\u2013605 (2002).","journal-title":"Mod. Pathol."},{"key":"788_CR37","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/bjc.2013.47","volume":"108","author":"G Nishikawa","year":"2013","unstructured":"Nishikawa, G. et al. Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. Br. J. Cancer 108, 951\u2013958 (2013).","journal-title":"Br. J. Cancer"},{"key":"788_CR38","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s00432-021-03589-4","volume":"147","author":"G Munari","year":"2021","unstructured":"Munari, G. et al. Molecular profiling of appendiceal serrated lesions, polyps and mucinous neoplasms: a single-centre experience. J. Cancer Res. Clin. Oncol. 147, 1897\u20131904 (2021).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"788_CR39","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/s41379-018-0003-0","volume":"31","author":"M Johncilla","year":"2018","unstructured":"Johncilla, M. et al. Mutational landscape of goblet cell carcinoids and adenocarcinoma ex goblet cell carcinoids of the appendix is distinct from typical carcinoids and colorectal adenocarcinomas. Mod. Pathol. 31, 989\u2013996 (2018).","journal-title":"Mod. Pathol."},{"key":"788_CR40","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/his.13986","volume":"76","author":"X Liao","year":"2020","unstructured":"Liao, X. et al. Mutation profile of high-grade appendiceal mucinous neoplasm. Histopathology 76, 461\u2013469 (2020).","journal-title":"Histopathology"},{"key":"788_CR41","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1158\/1535-7163.MCT-20-0318","volume":"19","author":"H Arai","year":"2020","unstructured":"Arai, H. et al. Molecular characterization of appendiceal goblet cell carcinoid. Mol. Cancer Ther. 19, 2634\u20132640 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"788_CR42","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1200\/JCO.22.01392","volume":"41","author":"MB Foote","year":"2023","unstructured":"Foote, M. B. et al. Molecular classification of appendiceal adenocarcinoma. J. Clin. Oncol. 41, 1553\u20131564 (2023).","journal-title":"J. Clin. Oncol."},{"key":"788_CR43","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.28644","volume":"3","author":"AN Holowatyj","year":"2020","unstructured":"Holowatyj, A. N., Eng, C., Wen, W., Idrees, K. & Guo, X. Spectrum of somatic cancer gene variations among adults with appendiceal cancer by age at disease onset. JAMA Netw. Open 3, e2028644 (2020).","journal-title":"JAMA Netw. Open"},{"key":"788_CR44","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1097\/PAS.0b013e318282649b","volume":"37","author":"MW Taggart","year":"2013","unstructured":"Taggart, M. W. et al. High-level microsatellite instability in appendiceal carcinomas. Am. J. Surg. Pathol. 37, 1192\u20131200 (2013).","journal-title":"Am. J. Surg. Pathol."},{"key":"788_CR45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/jamaoncol.2022.5425","volume":"9","author":"AN Holowatyj","year":"2022","unstructured":"Holowatyj, A. N., Washington, M. K., Tavtigian, S. V., Eng, C. & Horton, C. Inherited cancer susceptibility gene sequence variations among patients with appendix cancer. JAMA Oncol. 9, 95\u2013101 (2022). This study reports the prevalence and spectrum of cancer susceptibility gene sequence variations among patients with appendiceal tumours, revealing that 10% of patients who underwent testing for hereditary cancer predisposition carried a deleterious sequence variation in a cancer-susceptibility gene.","journal-title":"JAMA Oncol."},{"key":"788_CR46","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1158\/1078-0432.CCR-22-3956","volume":"29","author":"MB Foote","year":"2023","unstructured":"Foote, M. B. et al. The impact of germline alterations in appendiceal adenocarcinoma. Clin. Cancer Res. 29, 2631\u20132637 (2023).","journal-title":"Clin. Cancer Res."},{"key":"788_CR47","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/nrc2761","volume":"9","author":"DW Kufe","year":"2009","unstructured":"Kufe, D. W. Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer 9, 874\u2013885 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"788_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115613","volume":"9","author":"H Shibahara","year":"2014","unstructured":"Shibahara, H. et al. A comprehensive expression analysis of mucins in appendiceal carcinoma in a multicenter study: MUC3 is a novel prognostic factor. PLoS ONE 9, e115613 (2014).","journal-title":"PLoS ONE"},{"key":"788_CR49","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S0002-9440(10)64211-3","volume":"161","author":"JT O\u2019Connell","year":"2002","unstructured":"O\u2019Connell, J. T., Tomlinson, J. S., Roberts, A. A., McGonigle, K. F. & Barsky, S. H. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. Am. J. Pathol. 161, 551\u2013564 (2002).","journal-title":"Am. J. Pathol."},{"key":"788_CR50","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"788_CR51","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).","journal-title":"Sci. Signal."},{"key":"788_CR52","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jamcollsurg.2015.12.012","volume":"222","author":"EA Levine","year":"2016","unstructured":"Levine, E. A. et al. Prognostic molecular subtypes of low-grade cancer of the appendix. J. Am. Coll. Surg. 222, 493\u2013503 (2016).","journal-title":"J. Am. Coll. Surg."},{"key":"788_CR53","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1245\/s10434-020-08210-5","volume":"27","author":"J Su","year":"2020","unstructured":"Su, J. et al. Prognostic molecular classification of appendiceal mucinous neoplasms treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann. Surg. Oncol. 27, 1439\u20131447 (2020).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.12821","volume":"186","author":"IA Kooij","year":"2016","unstructured":"Kooij, I. A., Sahami, S., Meijer, S. L., Buskens, C. J. & Te Velde, A. A. The immunology of the vermiform appendix: a review of the literature. Clin. Exp. Immunol. 186, 1\u20139 (2016).","journal-title":"Clin. Exp. Immunol."},{"key":"788_CR55","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2021.12.012","volume":"55","author":"NM Chapman","year":"2022","unstructured":"Chapman, N. M. & Chi, H. Metabolic adaptation of lymphocytes in immunity and disease. Immunity 55, 14\u201330 (2022).","journal-title":"Immunity"},{"key":"788_CR56","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1245\/s10434-023-13587-0","volume":"30","author":"EA Hanse","year":"2023","unstructured":"Hanse, E. A. et al. A novel assessment of metabolic pathways in peritoneal metastases from low-grade appendiceal mucinous neoplasms. Ann. Surg. Oncol. 30, 5132\u20135141 (2023).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR57","doi-asserted-by":"publisher","first-page":"e00366","DOI":"10.1128\/mBio.00366-12","volume":"4","author":"CM Guinane","year":"2013","unstructured":"Guinane, C. M. et al. Microbial composition of human appendices from patients following appendectomy. mBio 4, e00366\u2013e00412 (2013).","journal-title":"mBio"},{"key":"788_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/CS20180956","volume":"133","author":"L Vitetta","year":"2019","unstructured":"Vitetta, L., Chen, J. & Clarke, S. The vermiform appendix: an immunological organ sustaining a microbiome inoculum. Clin. Sci. 133, 1\u20138 (2019).","journal-title":"Clin. Sci."},{"key":"788_CR59","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1099\/00222615-21-3-245","volume":"21","author":"KM Elhag","year":"1986","unstructured":"Elhag, K. M., Alwan, M. H., Al-Adnani, M. S. & Sherif, R. A. Bacteroides fragilis is a silent pathogen in acute appendicitis. J. Med. Microbiol. 21, 245\u2013249 (1986).","journal-title":"J. Med. Microbiol."},{"key":"788_CR60","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1136\/adc.63.5.536","volume":"63","author":"JP Roberts","year":"1988","unstructured":"Roberts, J. P. Quantitative bacterial flora of acute appendicitis. Arch. Dis. Child. 63, 536\u2013540 (1988).","journal-title":"Arch. Dis. Child."},{"key":"788_CR61","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/gut.2009.191320","volume":"60","author":"A Swidsinski","year":"2011","unstructured":"Swidsinski, A. et al. Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum\/necrophorum. Gut 60, 34\u201340 (2011).","journal-title":"Gut"},{"key":"788_CR62","doi-asserted-by":"publisher","first-page":"2145845","DOI":"10.1080\/19490976.2022.2145845","volume":"15","author":"M Blohs","year":"2023","unstructured":"Blohs, M. et al. Acute appendicitis manifests as two microbiome state types with oral pathogens influencing severity. Gut Microbes 15, 2145845 (2023).","journal-title":"Gut Microbes"},{"key":"788_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05205-8","volume":"22","author":"N Dadgar","year":"2024","unstructured":"Dadgar, N. et al. Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis. J. Transl. Med. 22, 402 (2024).","journal-title":"J. Transl. Med."},{"key":"788_CR64","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202215914","volume":"15","author":"S Bootsma","year":"2023","unstructured":"Bootsma, S., Bijlsma, M. F. & Vermeulen, L. The molecular biology of peritoneal metastatic disease. EMBO Mol. Med. 15, e15914 (2023).","journal-title":"EMBO Mol. Med."},{"key":"788_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-105","volume":"8","author":"JJ Gilbreath","year":"2013","unstructured":"Gilbreath, J. J. et al. A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei. Orphanet J. Rare Dis. 8, 105 (2013).","journal-title":"Orphanet J. Rare Dis."},{"key":"788_CR66","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1158\/1541-7786.MCR-23-0749","volume":"22","author":"VK Pattalachinti","year":"2024","unstructured":"Pattalachinti, V. K. et al. Peritoneal microenvironment promotes appendiceal adenocarcinoma growth: a multi-omics approach using patient-derived xenografts. Mol. Cancer Res. 22, 329\u2013336 (2024). This study shows that the peritoneal TME promotes the growth of appendiceal tumours and upregulates genes related to cell proliferation in orthotopic and flank-implanted PDXs.","journal-title":"Mol. Cancer Res."},{"key":"788_CR67","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1245\/s10434-013-3261-6","volume":"21","author":"K Lohani","year":"2014","unstructured":"Lohani, K. et al. Pseudomyxoma peritonei: inflammatory responses in the peritoneal microenvironment. Ann. Surg. Oncol. 21, 1441\u20131447 (2014).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR68","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1200\/JCO.2023.41.16_suppl.3622","volume":"41","author":"M Rehman","year":"2023","unstructured":"Rehman, M. et al. Molecular profiling and characterization of the tumor immune microenvironment (TME) in appendiceal carcinoma (AC). J. Clin. Oncol. 41, 3622 (2023).","journal-title":"J. Clin. Oncol."},{"key":"788_CR69","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3390\/cancers12061544","volume":"12","author":"MGK Benesch","year":"2020","unstructured":"Benesch, M. G. K. & Mathieson, A. Epidemiology of signet ring cell adenocarcinomas. Cancers 12, 1544 (2020).","journal-title":"Cancers"},{"key":"788_CR70","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.3390\/cancers15092497","volume":"15","author":"M Enblad","year":"2023","unstructured":"Enblad, M. et al. Signet ring cell colorectal and appendiceal cancer: a small signet ring cell component is also associated with poor outcome. Cancers 15, 2497 (2023).","journal-title":"Cancers"},{"key":"788_CR71","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/PAP.0000000000000153","volume":"24","author":"Z Volynskaya","year":"2017","unstructured":"Volynskaya, Z., Evans, A. J. & Asa, S. L. Clinical applications of whole-slide imaging in anatomic pathology. Adv. Anat. Pathol. 24, 215\u2013221 (2017).","journal-title":"Adv. Anat. Pathol."},{"key":"788_CR72","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/jclinpath-2020-206762","volume":"74","author":"AJ Evans","year":"2021","unstructured":"Evans, A. J., Vajpeyi, R., Henry, M. & Chetty, R. Establishment of a remote diagnostic histopathology service using whole slide imaging (digital pathology). J. Clin. Pathol. 74, 421\u2013424 (2021).","journal-title":"J. Clin. Pathol."},{"key":"788_CR73","doi-asserted-by":"publisher","first-page":"434","DOI":"10.5858\/arpa.2022-0023-CP","volume":"147","author":"DJ Gross","year":"2023","unstructured":"Gross, D. J. et al. Strong job market for pathologists: results from the 2021 college of American Pathologists Practice Leader Survey. Arch. Pathol. Lab. Med. 147, 434\u2013441 (2023).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"788_CR74","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.5858\/133.12.1949","volume":"133","author":"DC Wilbur","year":"2009","unstructured":"Wilbur, D. C. et al. Whole-slide imaging digital pathology as a platform for teleconsultation: a pilot study using paired subspecialist correlations. Arch. Pathol. Lab. Med. 133, 1949\u20131953 (2009).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"788_CR75","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s10278-013-9572-0","volume":"26","author":"G Romero Lauro","year":"2013","unstructured":"Romero Lauro, G. et al. Digital pathology consultations \u2014 a new era in digital imaging, challenges and practical applications. J. Digit. Imaging 26, 668\u2013677 (2013).","journal-title":"J. Digit. Imaging"},{"key":"788_CR76","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1155\/2012\/124076","volume":"35","author":"E Ayad","year":"2012","unstructured":"Ayad, E. & Yagi, Y. Virtual microscopy beyond the pyramids, applications of WSI in Cairo University for E-education & telepathology. Anal. Cell Pathol. 35, 93\u201395 (2012).","journal-title":"Anal. Cell Pathol."},{"key":"788_CR77","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/2153-3539.170650","volume":"6","author":"C Zhao","year":"2015","unstructured":"Zhao, C. et al. International telepathology consultation: three years of experience between the University of Pittsburgh Medical Center and KingMed Diagnostics in China. J. Pathol. Inform. 6, 63 (2015).","journal-title":"J. Pathol. Inform."},{"key":"788_CR78","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41416-020-01122-x","volume":"124","author":"A Echle","year":"2021","unstructured":"Echle, A. et al. Deep learning in cancer pathology: a new generation of clinical biomarkers. Br. J. Cancer 124, 686\u2013696 (2021).","journal-title":"Br. J. Cancer"},{"key":"788_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17678-4","volume":"11","author":"B Schmauch","year":"2020","unstructured":"Schmauch, B. et al. A deep learning model to predict RNA-seq expression of tumours from whole slide images. Nat. Commun. 11, 3877 (2020).","journal-title":"Nat. Commun."},{"key":"788_CR80","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/s43018-020-0085-8","volume":"1","author":"Y Fu","year":"2020","unstructured":"Fu, Y. et al. Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis. Nat. Cancer 1, 800\u2013810 (2020).","journal-title":"Nat. Cancer"},{"key":"788_CR81","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s43018-020-0087-6","volume":"1","author":"JN Kather","year":"2020","unstructured":"Kather, J. N. et al. Pan-cancer image-based detection of clinically actionable genetic alterations. Nat. Cancer 1, 789\u2013799 (2020).","journal-title":"Nat. Cancer"},{"key":"788_CR82","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1038\/s41591-018-0177-5","volume":"24","author":"N Coudray","year":"2018","unstructured":"Coudray, N. et al. Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat. Med. 24, 1559\u20131567 (2018).","journal-title":"Nat. Med."},{"key":"788_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-55228-w","volume":"14","author":"O Eminaga","year":"2024","unstructured":"Eminaga, O. et al. Critical evaluation of artificial intelligence as a digital twin of pathologists for prostate cancer pathology. Sci. Rep. 14, 5284 (2024).","journal-title":"Sci. Rep."},{"key":"788_CR84","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.5858\/arpa.2022-0457-RA","volume":"147","author":"Y Liu","year":"2023","unstructured":"Liu, Y., Han, D., Parwani, A. V. & Li, Z. Applications of artificial intelligence in breast pathology. Arch. Pathol. Lab. Med. 147, 1003\u20131013 (2023).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"788_CR85","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1053\/j.gastro.2020.06.021","volume":"159","author":"A Echle","year":"2020","unstructured":"Echle, A. et al. Clinical-grade detection of microsatellite instability in colorectal tumors by deep learning. Gastroenterology 159, 1406\u20131416.e11 (2020).","journal-title":"Gastroenterology"},{"key":"788_CR86","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/gutjnl-2019-319866","volume":"70","author":"K Sirinukunwattana","year":"2021","unstructured":"Sirinukunwattana, K. et al. Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning. Gut 70, 544\u2013554 (2021).","journal-title":"Gut"},{"key":"788_CR87","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/ajcp\/aqv023","volume":"145","author":"RS Goswami","year":"2016","unstructured":"Goswami, R. S. et al. Identification of factors affecting the success of next-generation sequencing testing in solid tumors. Am. J. Clin. Pathol. 145, 222\u2013237 (2016).","journal-title":"Am. J. Clin. Pathol."},{"key":"788_CR88","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1245\/s10434-020-08841-8","volume":"27","author":"O Moaven","year":"2020","unstructured":"Moaven, O. et al. Clinical implications of genetic signatures in appendiceal cancer patients with incomplete cytoreduction\/HIPEC. Ann. Surg. Oncol. 27, 5016\u20135023 (2020).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR89","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1159\/000536219","volume":"102","author":"K Takane","year":"2024","unstructured":"Takane, K. et al. Genome-wide analysis of DNA methylation in pseudomyxoma peritonei originated from appendiceal neoplasms. Oncology 102, 720\u2013731 (2024). This study investigates global DNA methylation profiles in 15 PMP tumours of appendiceal origin and identifies two distinct epigenotypes, supporting the need for large-scale, multi-omics studies of appendiceal tumours that include the epigenome.","journal-title":"Oncology"},{"key":"788_CR90","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1158\/1055-9965.EPI-05-0456","volume":"14","author":"CP Wild","year":"2005","unstructured":"Wild, C. P. Complementing the genome with an \u201cexposome\u201d: the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol. Biomark. Prev. 14, 1847\u20131850 (2005).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"788_CR91","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.cell.2021.01.043","volume":"184","author":"A Peters","year":"2021","unstructured":"Peters, A., Nawrot, T. S. & Baccarelli, A. A. Hallmarks of environmental insults. Cell 184, 1455\u20131468 (2021).","journal-title":"Cell"},{"key":"788_CR92","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41568-021-00356-y","volume":"21","author":"AN Holowatyj","year":"2021","unstructured":"Holowatyj, A. N., Perea, J. & Lieu, C. H. Gut instinct: a call to study the biology of early-onset colorectal cancer disparities. Nat. Rev. Cancer 21, 339\u2013340 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"788_CR93","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ajhg.2010.03.011","volume":"86","author":"CD Royal","year":"2010","unstructured":"Royal, C. D. et al. Inferring genetic ancestry: opportunities, challenges, and implications. Am. J. Hum. Genet. 86, 661\u2013673 (2010).","journal-title":"Am. J. Hum. Genet."},{"key":"788_CR94","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/NEJMc2213457","volume":"388","author":"DA Mata","year":"2023","unstructured":"Mata, D. A., Rotenstein, L. S., Ramos, M. A. & Jena, A. B. Disparities according to genetic ancestry in the use of precision oncology assays. N. Engl. J. Med. 388, 281\u2013283 (2023).","journal-title":"N. Engl. J. Med."},{"key":"788_CR95","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.3390\/ijerph19052598","volume":"19","author":"A Hoadley","year":"2022","unstructured":"Hoadley, A. et al. The role of medical mistrust in concerns about tumor genomic profiling among Black and African American cancer patients. Int. J. Environ. Res. Public Health 19, 2598 (2022).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"788_CR96","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1158\/2767-9764.CRC-24-0019","volume":"4","author":"NJ Hornstein","year":"2024","unstructured":"Hornstein, N. J. et al. Efficacy and safety of atezolizumab and bevacizumab in appendiceal adenocarcinoma. Cancer Res. Commun. 4, 1363\u20131368 (2024).","journal-title":"Cancer Res. Commun."},{"key":"788_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19015-1","volume":"11","author":"F Avila Cobos","year":"2020","unstructured":"Avila Cobos, F., Alquicira-Hernandez, J., Powell, J. E., Mestdagh, P. & De Preter, K. Benchmarking of cell type deconvolution pipelines for transcriptomics data. Nat. Commun. 11, 5650 (2020).","journal-title":"Nat. Commun."},{"key":"788_CR98","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/iep.12011","volume":"94","author":"A Byron","year":"2013","unstructured":"Byron, A., Humphries, J. D. & Humphries, M. J. Defining the extracellular matrix using proteomics. Int. J. Exp. Pathol. 94, 75\u201392 (2013).","journal-title":"Int. J. Exp. Pathol."},{"key":"788_CR99","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.it.2022.11.002","volume":"44","author":"C Villemin","year":"2023","unstructured":"Villemin, C. et al. The heightened importance of the microbiome in cancer immunotherapy. Trends Immunol. 44, 44\u201359 (2023).","journal-title":"Trends Immunol."},{"key":"788_CR100","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197\u2013218 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"788_CR101","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/00004347-198506000-00003","volume":"4","author":"MJ Merino","year":"1985","unstructured":"Merino, M. J., Edmonds, P. & LiVolsi, V. Appendiceal carcinoma metastatic to the ovaries and mimicking primary ovarian tumors. Int. J. Gynecol. Pathol. 4, 110\u2013120 (1985).","journal-title":"Int. J. Gynecol. Pathol."},{"key":"788_CR102","doi-asserted-by":"publisher","first-page":"9120","DOI":"10.3390\/ijms21239120","volume":"21","author":"ML Calabro","year":"2020","unstructured":"Calabro, M. L., Lazzari, N., Rigotto, G., Tonello, M. & Sommariva, A. Role of epithelial-mesenchymal plasticity in pseudomyxoma peritonei: implications for locoregional treatments. Int. J. Mol. Sci. 21, 9120 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"788_CR103","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.ejso.2014.06.006","volume":"40","author":"D Elias","year":"2014","unstructured":"Elias, D. et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur. J. Surg. Oncol. 40, 1467\u20131473 (2014).","journal-title":"Eur. J. Surg. Oncol."},{"key":"788_CR104","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1245\/s10434-023-14553-6","volume":"31","author":"PL Wagner","year":"2024","unstructured":"Wagner, P. L. et al. Characterizing the immune environment in peritoneal carcinomatosis: insights for novel immunotherapy strategies. Ann. Surg. Oncol. 31, 2069\u20132077 (2024).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR105","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41416-024-02717-4","volume":"131","author":"C Ramos","year":"2024","unstructured":"Ramos, C., Gerakopoulos, V. & Oehler, R. Metastasis-associated fibroblasts in peritoneal surface malignancies. Br. J. Cancer 131, 407\u2013419 (2024).","journal-title":"Br. J. Cancer"},{"key":"788_CR106","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41575-018-0053-2","volume":"15","author":"CM Ulrich","year":"2018","unstructured":"Ulrich, C. M., Himbert, C., Holowatyj, A. N. & Hursting, S. D. Energy balance and gastrointestinal cancer: risk, interventions, outcomes and mechanisms. Nat. Rev. Gastroenterol. Hepatol. 15, 683\u2013698 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"788_CR107","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1158\/1940-6207.CAPR-19-0538","volume":"13","author":"AN Holowatyj","year":"2020","unstructured":"Holowatyj, A. N. et al. Multi-omics analysis reveals adipose-tumor crosstalk in patients with colorectal cancer. Cancer Prev. Res. 13, 817\u2013828 (2020).","journal-title":"Cancer Prev. Res."},{"key":"788_CR108","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41416-020-0898-3","volume":"123","author":"M Natsume","year":"2020","unstructured":"Natsume, M. et al. Omental adipocytes promote peritoneal metastasis of gastric cancer through the CXCL2-VEGFA axis. Br. J. Cancer 123, 459\u2013470 (2020).","journal-title":"Br. J. Cancer"},{"key":"788_CR109","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1038\/s41388-023-02707-5","volume":"42","author":"K Liu","year":"2023","unstructured":"Liu, K. et al. Peritoneal high-fat environment promotes peritoneal metastasis of gastric cancer cells through activation of NSUN2-mediated ORAI2 m5C modification. Oncogene 42, 1980\u20131993 (2023).","journal-title":"Oncogene"},{"key":"788_CR110","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1158\/1078-0432.CCR-16-1406","volume":"23","author":"PH Watson","year":"2017","unstructured":"Watson, P. H. Biospecimen complexity \u2014 the next challenge for cancer research biobanks? Clin. Cancer Res. 23, 894\u2013898 (2017).","journal-title":"Clin. Cancer Res."},{"key":"788_CR111","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.1245\/s10434-024-15355-0","volume":"31","author":"N Wajih","year":"2024","unstructured":"Wajih, N. et al. Enhancing the efficacy of HIPEC through bromelain: a preclinical investigation in appendiceal cancer. Ann. Surg. Oncol. 31, 5377\u20135389 (2024).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR112","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1245\/s10434-018-7008-2","volume":"26","author":"KI Votanopoulos","year":"2019","unstructured":"Votanopoulos, K. I. et al. Appendiceal cancer patient-specific tumor organoid model for predicting chemotherapy efficacy prior to initiation of treatment: a feasibility study. Ann. Surg. Oncol. 26, 139\u2013147 (2019). This study demonstrates the feasibility of biofabricating organoids from metastatic peritoneal tissues of LAMN and HAMN origin for personalized drug screening.","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR113","doi-asserted-by":"publisher","first-page":"5141","DOI":"10.1158\/1078-0432.CCR-21-0982","volume":"27","author":"SD Forsythe","year":"2021","unstructured":"Forsythe, S. D. et al. Organoid platform in preclinical investigation of personalized immunotherapy efficacy in appendiceal cancer: feasibility study. Clin. Cancer Res. 27, 5141\u20135150 (2021).","journal-title":"Clin. Cancer Res."},{"key":"788_CR114","doi-asserted-by":"publisher","first-page":"4950","DOI":"10.1245\/s10434-020-08790-2","volume":"27","author":"SD Forsythe","year":"2020","unstructured":"Forsythe, S. D. et al. Personalized identification of optimal HIPEC perfusion protocol in patient-derived tumor organoid platform. Ann. Surg. Oncol. 27, 4950\u20134960 (2020).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR115","first-page":"910","volume":"14","author":"M Kapalczynska","year":"2018","unstructured":"Kapalczynska, M. et al. 2D and 3D cell cultures \u2014 a comparison of different types of cancer cell cultures. Arch. Med. Sci. 14, 910\u2013919 (2018).","journal-title":"Arch. Med. Sci."},{"key":"788_CR116","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jcp.24683","volume":"230","author":"M Ravi","year":"2015","unstructured":"Ravi, M., Paramesh, V., Kaviya, S. R., Anuradha, E. & Solomon, F. D. 3D cell culture systems: advantages and applications. J. Cell Physiol. 230, 16\u201326 (2015).","journal-title":"J. Cell Physiol."},{"key":"788_CR117","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost, J. & Clevers, H. Organoids in cancer research. Nat. Rev. Cancer 18, 407\u2013418 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"788_CR118","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1158\/1078-0432.CCR-22-0980","volume":"28","author":"J Weitz","year":"2022","unstructured":"Weitz, J. et al. An ex vivo organotypic culture platform for functional interrogation of human appendiceal cancer reveals a prominent and heterogenous immunological landscape. Clin. Cancer Res. 28, 4793\u20134806 (2022). This study utilizes an ex vivo slice model to study cellular interactions within the peritoneal TME of appendiceal origin, and delivers a new approach for interrogating appendiceal tumour pathophysiology and therapeutics in the preclinical setting.","journal-title":"Clin. Cancer Res."},{"key":"788_CR119","doi-asserted-by":"publisher","unstructured":"Weitz, J. et al. Cyclin-dependent kinase 4\/6 inhibition as a novel therapy for peritoneal mucinous carcinomatosis with GNAS mutations. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.24.00511 (2024).","DOI":"10.1200\/JCO.24.00511"},{"key":"788_CR120","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s43586-022-00118-6","volume":"2","author":"CM Leung","year":"2022","unstructured":"Leung, C. M. et al. A guide to the organ-on-a-chip. Nat. Rev. Methods Primers\u00a02, 33 (2022).","journal-title":"Nat. Rev. Methods Primers"},{"key":"788_CR121","first-page":"4051","volume":"29","author":"TC Chua","year":"2009","unstructured":"Chua, T. C., Akther, J., Yao, P. & Morris, D. L. In vivo model of pseudomyxoma peritonei for novel candidate drug discovery. Anticancer. Res. 29, 4051\u20134055 (2009).","journal-title":"Anticancer. Res."},{"key":"788_CR122","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1016\/j.ajpath.2014.03.004","volume":"184","author":"A Dohan","year":"2014","unstructured":"Dohan, A. et al. Orthotopic animal model of pseudomyxoma peritonei: an in vivo model to test anti-angiogenic drug effects. Am. J. Pathol. 184, 1920\u20131929 (2014).","journal-title":"Am. J. Pathol."},{"key":"788_CR123","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40164-023-00465-4","volume":"12","author":"MC Vazquez-Borrego","year":"2023","unstructured":"Vazquez-Borrego, M. C. et al. Antitumor effect of a small-molecule inhibitor of KRAS(G12D) in xenograft models of mucinous appendicular neoplasms. Exp. Hematol. Oncol. 12, 102 (2023).","journal-title":"Exp. Hematol. Oncol."},{"key":"788_CR124","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1365-2613.2010.00721.x","volume":"91","author":"AA Mavanur","year":"2010","unstructured":"Mavanur, A. A. et al. Establishment and characterization of a murine xenograft model of appendiceal mucinous adenocarcinoma. Int. J. Exp. Pathol. 91, 357\u2013367 (2010).","journal-title":"Int. J. Exp. Pathol."},{"key":"788_CR125","unstructured":"The Jackson Laboratory. Mouse Models of Human Cancer Database: PDX model details TM00351. JAX https:\/\/tumor.informatics.jax.org\/mtbwi\/pdxDetails.do?modelID=TM00351 (2024)."},{"key":"788_CR126","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/cam4.640","volume":"5","author":"MR Kuracha","year":"2016","unstructured":"Kuracha, M. R., Thomas, P., Loggie, B. W. & Govindarajan, V. Patient-derived xenograft mouse models of pseudomyxoma peritonei recapitulate the human inflammatory tumor microenvironment. Cancer Med. 5, 711\u2013719 (2016).","journal-title":"Cancer Med."},{"key":"788_CR127","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.humpath.2009.12.013","volume":"41","author":"K Flatmark","year":"2010","unstructured":"Flatmark, K. et al. Exploring the peritoneal surface malignancy phenotype \u2014 a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models. Hum. Pathol. 41, 1109\u20131119 (2010).","journal-title":"Hum. Pathol."},{"key":"788_CR128","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-7-116","volume":"7","author":"K Flatmark","year":"2007","unstructured":"Flatmark, K. et al. Pseudomyxoma peritonei \u2014 two novel orthotopic mouse models portray the PMCA-I histopathologic subtype. BMC Cancer 7, 116 (2007).","journal-title":"BMC Cancer"},{"key":"788_CR129","unstructured":"Holowatyj Laboratory. Genetics of Appendix Cancer (GAP) Study. VUMC https:\/\/www.gapcancerstudy.org (2022)."},{"key":"788_CR130","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/study\/NCT05734430 (2024)."},{"key":"788_CR131","unstructured":"National Comprehensive Cancer Network. NCCN guidelines: colon cancer. NCCN https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1428 (2025)."},{"key":"788_CR132","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.16161","volume":"6","author":"JP Shen","year":"2023","unstructured":"Shen, J. P. et al. Efficacy of systemic chemotherapy in patients with low-grade mucinous appendiceal adenocarcinoma: a randomized crossover trial. JAMA Netw. Open 6, e2316161 (2023).","journal-title":"JAMA Netw. Open"},{"key":"788_CR133","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.clcc.2023.08.005","volume":"22","author":"F Ghelardi","year":"2023","unstructured":"Ghelardi, F. et al. Mytomicin-C, metronomic capecitabine, and bevacizumab in patients with unresectable or relapsed pseudomyxoma peritonei of appendiceal origin. Clin. Colorectal Cancer 22, 450\u2013456.e1 (2023).","journal-title":"Clin. Colorectal Cancer"},{"key":"788_CR134","doi-asserted-by":"publisher","first-page":"8138","DOI":"10.1245\/s10434-023-13501-8","volume":"30","author":"MG White","year":"2023","unstructured":"White, M. G. et al. Treatment variation and long-term outcomes of low-grade appendiceal neoplasms. Ann. Surg. Oncol. 30, 8138\u20138143 (2023).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR135","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/bjs.4393","volume":"91","author":"S Gonzalez-Moreno","year":"2004","unstructured":"Gonzalez-Moreno, S. & Sugarbaker, P. H. Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br. J. Surg. 91, 304\u2013311 (2004).","journal-title":"Br. J. Surg."},{"key":"788_CR136","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/cncr.29744","volume":"122","author":"EA Asare","year":"2016","unstructured":"Asare, E. A. et al. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: analysis of the National Cancer Data Base. Cancer 122, 213\u2013221 (2016).","journal-title":"Cancer"},{"key":"788_CR137","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1245\/s10434-012-2241-6","volume":"19","author":"F Austin","year":"2012","unstructured":"Austin, F. et al. Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. Ann. Surg. Oncol. 19, 1386\u20131393 (2012).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR138","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Quenet","year":"2021","unstructured":"Quenet, F. et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 22, 256\u2013266 (2021).","journal-title":"Lancet Oncol."},{"key":"788_CR139","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(20)30322-3","volume":"21","author":"D Goere","year":"2020","unstructured":"Goere, D. et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol. 21, 1147\u20131154 (2020).","journal-title":"Lancet Oncol."},{"key":"788_CR140","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1200\/JCO.22.02644","volume":"42","author":"ES Zwanenburg","year":"2024","unstructured":"Zwanenburg, E. S. et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): 5-year results of a randomized multicenter trial. J. Clin. Oncol. 42, 140\u2013145 (2024).","journal-title":"J. Clin. Oncol."},{"key":"788_CR141","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021546","volume":"99","author":"M Ba","year":"2020","unstructured":"Ba, M. et al. Cytoreductive surgery and HIPEC for malignant ascites from colorectal cancer \u2014 a randomized study. Medicine 99, e21546 (2020).","journal-title":"Medicine"},{"key":"788_CR142","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/BF02987754","volume":"9","author":"FN Gilly","year":"1992","unstructured":"Gilly, F. N. et al. Treatment of malignant peritoneal effusion in digestive and ovarian cancer. Med. Oncol. Tumor Pharmacother. 9, 177\u2013181 (1992).","journal-title":"Med. Oncol. Tumor Pharmacother."},{"key":"788_CR143","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s004230050246","volume":"384","author":"PH Sugarbaker","year":"1999","unstructured":"Sugarbaker, P. H. Management of peritoneal-surface malignancy: the surgeon\u2019s role. Langenbecks Arch. Surg. 384, 576\u2013587 (1999).","journal-title":"Langenbecks Arch. Surg."},{"key":"788_CR144","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet, P. & Sugarbaker, P. H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat. Res. 82, 359\u2013374 (1996).","journal-title":"Cancer Treat. Res."},{"key":"788_CR145","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1245\/s10434-015-4446-y","volume":"22","author":"SP Dineen","year":"2015","unstructured":"Dineen, S. P. et al. A simplified preoperative assessment predicts complete cytoreduction and outcomes in patients with low-grade mucinous adenocarcinoma of the appendix. Ann. Surg. Oncol. 22, 3640\u20133646 (2015).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR146","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/bjs.10527","volume":"104","author":"A Dohan","year":"2017","unstructured":"Dohan, A. et al. Evaluation of the peritoneal carcinomatosis index with CT and MRI. Br. J. Surg. 104, 1244\u20131249 (2017).","journal-title":"Br. J. Surg."},{"key":"788_CR147","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1200\/JCO.2010.33.2056","volume":"29","author":"MH Kulke","year":"2011","unstructured":"Kulke, M. H. et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J. Clin. Oncol. 29, 934\u2013943 (2011).","journal-title":"J. Clin. Oncol."},{"key":"788_CR148","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejso.2019.10.033","volume":"47","author":"SJ Valle","year":"2021","unstructured":"Valle, S. J. et al. A novel treatment of bromelain and acetylcysteine (BromAc) in patients with peritoneal mucinous tumours: a phase I first in man study. Eur. J. Surg. Oncol. 47, 115\u2013122 (2021).","journal-title":"Eur. J. Surg. Oncol."},{"key":"788_CR149","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1038\/s41388-022-02388-6","volume":"41","author":"A More","year":"2022","unstructured":"More, A. et al. Oncogene addiction to GNAS in GNAS(R201) mutant tumors. Oncogene 41, 4159\u20134168 (2022).","journal-title":"Oncogene"},{"key":"788_CR150","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","volume":"629","author":"M Holderfield","year":"2024","unstructured":"Holderfield, M. et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature 629, 919\u2013926 (2024).","journal-title":"Nature"},{"key":"788_CR151","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.22515","volume":"6","author":"H Pittell","year":"2023","unstructured":"Pittell, H. et al. Racial and ethnic inequities in US oncology clinical trial participation from 2017 to 2022. JAMA Netw. Open 6, e2322515 (2023).","journal-title":"JAMA Netw. Open"},{"key":"788_CR152","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1245\/s10434-018-07120-x","volume":"26","author":"VA Francescutti","year":"2019","unstructured":"Francescutti, V. A. et al. Characterizing the patient experience of CS\/HIPEC through in-depth interviews with patients: identification of key concepts in the development of a patient-centered program. Ann. Surg. Oncol. 26, 1063\u20131070 (2019).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR153","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/PROM.S156279","volume":"9","author":"R Mercieca-Bebber","year":"2018","unstructured":"Mercieca-Bebber, R., King, M. T., Calvert, M. J., Stockler, M. R. & Friedlander, M. The importance of patient-reported outcomes in clinical trials and strategies for future optimization. Patient Relat. Outcome Meas. 9, 353\u2013367 (2018).","journal-title":"Patient Relat. Outcome Meas."},{"key":"788_CR154","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1245\/s10434-019-08064-6","volume":"27","author":"O Moaven","year":"2020","unstructured":"Moaven, O. et al. Health-related quality of life after cytoreductive surgery\/HIPEC for mucinous appendiceal cancer: results of a multicenter randomized trial comparing oxaliplatin and mitomycin. Ann. Surg. Oncol. 27, 772\u2013780 (2020).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR155","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1200\/JCO.2006.08.2644","volume":"24","author":"GY Locker","year":"2006","unstructured":"Locker, G. Y. et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 24, 5313\u20135327 (2006).","journal-title":"J. Clin. Oncol."},{"key":"788_CR156","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.ejso.2010.05.024","volume":"36","author":"A Ross","year":"2010","unstructured":"Ross, A., Sardi, A., Nieroda, C., Merriman, B. & Gushchin, V. Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC. Eur. J. Surg. Oncol. 36, 772\u2013776 (2010).","journal-title":"Eur. J. Surg. Oncol."},{"key":"788_CR157","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.0260","volume":"7","author":"A Yousef","year":"2024","unstructured":"Yousef, A. et al. Serum tumor markers and outcomes in patients with appendiceal adenocarcinoma. JAMA Netw. Open 7, e240260 (2024). This retrospective cohort study shows that CEA, CA19-9 and CA125 are all associated with overall survival of patients with appendiceal adenocarcinomas, which emphasizes the use of all three biomarkers in the clinical workup and surveillance for these patients, as well as the need to discover novel disease-specific biomarkers in this rare tumour setting.","journal-title":"JAMA Netw. Open"},{"key":"788_CR158","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1245\/s10434-007-9393-9","volume":"14","author":"D Baratti","year":"2007","unstructured":"Baratti, D. et al. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann. Surg. Oncol. 14, 2300\u20132308 (2007).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR159","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/jso.20107","volume":"87","author":"CP Carmignani","year":"2004","unstructured":"Carmignani, C. P., Hampton, R., Sugarbaker, C. E., Chang, D. & Sugarbaker, P. H. Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J. Surg. Oncol. 87, 162\u2013166 (2004).","journal-title":"J. Surg. Oncol."},{"key":"788_CR160","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s11605-021-05075-1","volume":"26","author":"W Nizam","year":"2022","unstructured":"Nizam, W. et al. Prognostic significance of preoperative tumor markers in pseudomyxoma peritonei from low-grade appendiceal mucinous neoplasm: a study from the US HIPEC collaborative. J. Gastrointest. Surg. 26, 414\u2013424 (2022).","journal-title":"J. Gastrointest. Surg."},{"key":"788_CR161","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00268-013-1988-7","volume":"37","author":"E Canbay","year":"2013","unstructured":"Canbay, E. et al. Preoperative carcinoembryonic antigen level predicts prognosis in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J. Surg. 37, 1271\u20131276 (2013).","journal-title":"World J. Surg."},{"key":"788_CR162","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1097\/SLA.0000000000005856","volume":"278","author":"A Dhiman","year":"2023","unstructured":"Dhiman, A. et al. Role of tumor-informed personalized circulating tumor DNA assay in informing recurrence in patients with peritoneal metastases from colorectal and high-grade appendix cancer undergoing curative-intent surgery. Ann. Surg. 278, 925\u2013931 (2023).","journal-title":"Ann. Surg."},{"key":"788_CR163","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1245\/s10434-018-6561-z","volume":"25","author":"JM Baumgartner","year":"2018","unstructured":"Baumgartner, J. M. et al. Preoperative circulating tumor DNA in patients with peritoneal carcinomatosis is an independent predictor of progression-free survival. Ann. Surg. Oncol. 25, 2400\u20132408 (2018).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR164","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00572","volume":"7","author":"H Singh","year":"2023","unstructured":"Singh, H. et al. Highly sensitive circulating tumor DNA assay aids clinical management of radiographically occult isolated peritoneal metastases in patients with GI cancer. JCO Precis. Oncol. 7, e2200572 (2023).","journal-title":"JCO Precis. Oncol."},{"key":"788_CR165","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12029-023-00959-8","volume":"55","author":"JM Baumgartner","year":"2024","unstructured":"Baumgartner, J. M. & Botta, G. P. Role of circulating tumor DNA among patients with colorectal peritoneal metastases. J. Gastrointest. Cancer 55, 41\u201346 (2024).","journal-title":"J. Gastrointest. Cancer"},{"key":"788_CR166","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00531","volume":"8","author":"E Belmont","year":"2024","unstructured":"Belmont, E. et al. Multi-institutional study evaluating the role of circulating tumor DNA in the management of appendiceal cancers. JCO Precis. Oncol. 8, e2300531 (2024). This multi-centre study of the utility of ctDNA identifies the detection of ctDNA with high accuracy in disease recurrence after a complete CRS for patients with grade 2\u20133 appendiceal tumours with peritoneal disease spread, and the study supports a role for ctDNA detection in the clinical management of these patients.","journal-title":"JCO Precis. Oncol."},{"key":"788_CR167","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/1754-9485.13329","volume":"66","author":"M Brassil","year":"2022","unstructured":"Brassil, M. et al. Appendiceal tumours \u2014 a correlation of CT features and histopathological diagnosis. J. Med. Imaging Radiat. Oncol. 66, 92\u2013101 (2022).","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"788_CR168","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/TA.0000000000002567","volume":"88","author":"H Kangaspunta","year":"2020","unstructured":"Kangaspunta, H. et al. Preoperative computed tomography is poor in detecting tumors of the appendix among patients with acute appendicitis: a cohort study of 5,224 appendectomies. J. Trauma Acute Care Surg. 88, 396\u2013401 (2020).","journal-title":"J. Trauma Acute Care Surg."},{"key":"788_CR169","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1245\/s10434-017-6052-7","volume":"24","author":"TL Sagebiel","year":"2017","unstructured":"Sagebiel, T. L. et al. Utility of appendiceal calcifications detected on computed tomography as a predictor for an underlying appendiceal epithelial neoplasm. Ann. Surg. Oncol. 24, 3667\u20133672 (2017).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR170","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1245\/s10434-023-14442-y","volume":"31","author":"AA Abreu","year":"2024","unstructured":"Abreu, A. A. et al. Cost analysis and financial implications of a peritoneal surface malignancy program in the USA. Ann. Surg. Oncol. 31, 630\u2013644 (2024).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR171","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1245\/s10434-023-14469-1","volume":"31","author":"I Solsky","year":"2024","unstructured":"Solsky, I. et al. Distance traveled and disparities in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann. Surg. Oncol. 31, 1035\u20131048 (2024).\u00a0This single-centre database study shows that over half of 1,614 patients, inclusive of patients with appendiceal tumours, travelled farther than 100 miles for CRS\u2009\u00b1\u2009HIPEC, which may lead to disparities in appendiceal tumour outcomes that are partly attributable to access to care and time to treatment.","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR172","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1245\/s10434-022-12437-9","volume":"30","author":"CT Ong","year":"2023","unstructured":"Ong, C. T. et al. Insurance authorization barriers in patients undergoing cytoreductive surgery and HIPEC. Ann. Surg. Oncol. 30, 417\u2013422 (2023).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR173","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1245\/s10434-023-14318-1","volume":"31","author":"M Vierra","year":"2024","unstructured":"Vierra, M. et al. Fragmentation of care in patients with peritoneal metastases undergoing cytoreductive surgery. Ann. Surg. Oncol. 31, 645\u2013654 (2024).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR174","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3322\/caac.21858","volume":"74","author":"F Islami","year":"2024","unstructured":"Islami, F. et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, 2019. CA Cancer J. Clin. 74, 405\u2013432 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"788_CR175","unstructured":"National Cancer Institute, Division of Cancer Control and Population Sciences. Appendiceal Cancer Consortium (APPECC). NCI-DCCPS https:\/\/epi.grants.cancer.gov\/cohort-consortium\/projecthub\/activeprojects\/project-proposal\/33\/ (2024)."},{"key":"788_CR176","doi-asserted-by":"publisher","first-page":"S172","DOI":"10.21037\/tlcr.2019.05.06","volume":"8","author":"V Jairam","year":"2019","unstructured":"Jairam, V. & Park, H. S. Strengths and limitations of large databases in lung cancer radiation oncology research. Transl. Lung Cancer Res. 8, S172\u2013S183 (2019).","journal-title":"Transl. Lung Cancer Res."},{"key":"788_CR177","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jnci\/djac193","volume":"115","author":"AM Bever","year":"2023","unstructured":"Bever, A. M. & Song, M. Early-life exposures and adulthood cancer risk: a life course perspective. J. Natl Cancer Inst. 115, 4\u20137 (2023).","journal-title":"J. Natl Cancer Inst."},{"key":"788_CR178","doi-asserted-by":"publisher","unstructured":"PSM Writing Group, PSM Consortium Group & Turaga, K. K. Consensus guideline for the management of malignant gastrointestinal obstruction in patients with peritoneal surface malignancies. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2024.04.09.24305427 (2024).","DOI":"10.1101\/2024.04.09.24305427"},{"key":"788_CR179","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1245\/s10434-020-08323-x","volume":"27","author":"Chicago Consensus Working Group.","year":"2020","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: palliative care considerations. Ann. Surg. Oncol. 27, 1798\u20131804 (2020). These consensus guidelines provide multidisciplinary recommendations for palliative care among patients with peritoneal surface malignancies, which include appendix tumours.","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR180","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1245\/s10434-023-14618-6","volume":"31","author":"R Balachandran","year":"2024","unstructured":"Balachandran, R., Thaysen, H. V., Christensen, P., Zachariae, R. & Iversen, L. H. Biopsychosocial late effects after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases from colorectal and appendiceal cancer: a national prospective cohort study. Ann. Surg. Oncol. 31, 1959\u20131969 (2024).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR181","doi-asserted-by":"publisher","first-page":"107045","DOI":"10.1016\/j.ejso.2023.107045","volume":"49","author":"V Kung","year":"2023","unstructured":"Kung, V. et al. Health related quality of life is excellent and sustained at two decades after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in survivors of pseudomyxoma peritonei of appendiceal origin. Eur. J. Surg. Oncol. 49, 107045 (2023).","journal-title":"Eur. J. Surg. Oncol."},{"key":"788_CR182","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1245\/s10434-012-2579-9","volume":"20","author":"N Tsilimparis","year":"2013","unstructured":"Tsilimparis, N. et al. Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk. Ann. Surg. Oncol. 20, 226\u2013232 (2013).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR183","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1245\/s10434-007-9678-z","volume":"15","author":"RP McQuellon","year":"2008","unstructured":"McQuellon, R. P. et al. Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin. Ann. Surg. Oncol. 15, 125\u2013133 (2008).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR184","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1245\/s10434-016-5547-y","volume":"23","author":"RM Dodson","year":"2016","unstructured":"Dodson, R. M. et al. Quality-of-life evaluation after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann. Surg. Oncol. 23, 772\u2013783 (2016).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR185","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jamcollsurg.2019.12.020","volume":"230","author":"KE Duckworth","year":"2020","unstructured":"Duckworth, K. E. et al. Caregiver quality of life before and after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J. Am. Coll. Surg. 230, 679\u2013687 (2020).","journal-title":"J. Am. Coll. Surg."},{"key":"788_CR186","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.jss.2022.11.061","volume":"283","author":"AP Sneider","year":"2023","unstructured":"Sneider, A. P. et al. Palliative care and characterization of symptoms in patients undergoing cytoreductive surgery\/hyperthermic intraperitoneal chemotherapy. J. Surg. Res. 283, 1154\u20131160 (2023).","journal-title":"J. Surg. Res."},{"key":"788_CR187","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jss.2016.11.066","volume":"211","author":"RS Morris","year":"2017","unstructured":"Morris, R. S. et al. Factors associated with palliative care use in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J. Surg. Res. 211, 79\u201386 (2017).","journal-title":"J. Surg. Res."},{"key":"788_CR188","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.14694\/EdBook_AM.2014.34.e57","volume":"34","author":"LM Morton","year":"2014","unstructured":"Morton, L. M., Onel, K., Curtis, R. E., Hungate, E. A. & Armstrong, G. T. The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults. Am. Soc. Clin. Oncol. Educ. Book 34, e57\u2013e67 (2014).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"788_CR189","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nrc3634","volume":"14","author":"LL Robison","year":"2014","unstructured":"Robison, L. L. & Hudson, M. M. Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nat. Rev. Cancer 14, 61\u201370 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"788_CR190","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/jso.25967","volume":"122","author":"JC Chen","year":"2020","unstructured":"Chen, J. C. et al. Outcomes of neoadjuvant chemotherapy before CRS-HIPEC for patients with appendiceal cancer. J. Surg. Oncol. 122, 388\u2013398 (2020).","journal-title":"J. Surg. Oncol."},{"key":"788_CR191","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1245\/s10434-020-08843-6","volume":"27","author":"AC Gamboa","year":"2020","unstructured":"Gamboa, A. C. et al. Implications of postoperative complications for survival after cytoreductive surgery and HIPEC: a multi-institutional analysis of the US HIPEC collaborative. Ann. Surg. Oncol. 27, 4980\u20134995 (2020).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR192","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jss.2023.06.054","volume":"292","author":"G SenthilKumar","year":"2023","unstructured":"SenthilKumar, G. et al. Prediction of early recurrence following CRS\/HIPEC in patients with disseminated appendiceal cancer. J. Surg. Res. 292, 275\u2013288 (2023).","journal-title":"J. Surg. Res."},{"key":"788_CR193","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41379-019-0216-x","volume":"32","author":"CA Arnold","year":"2019","unstructured":"Arnold, C. A. et al. Knowledge gaps in the appendix: a multi-institutional study from seven academic centers. Mod. Pathol. 32, 988\u2013996 (2019).","journal-title":"Mod. Pathol."},{"key":"788_CR194","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1245\/s10434-020-09499-y","volume":"28","author":"JM Baumgartner","year":"2021","unstructured":"Baumgartner, J. M. et al. A multi-institutional study of peritoneal recurrence following resection of low-grade appendiceal mucinous neoplasms. Ann. Surg. Oncol. 28, 4685\u20134694 (2021).","journal-title":"Ann. Surg. Oncol."},{"key":"788_CR195","unstructured":"Misdraji, J. et al. in WHO Classification of Tumours Series 5th edn Vol. 4 Ch. 34 (IARC, 2024)."}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41568-024-00788-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-024-00788-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-024-00788-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T07:58:51Z","timestamp":1743235131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41568-024-00788-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":195,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["788"],"URL":"https:\/\/doi.org\/10.1038\/s41568-024-00788-2","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"12 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.N.H. is Chair of the Scientific Advisory Board for the Appendix Cancer Pseudomyxoma Peritonei (ACPMP) Research Foundation and is on the American Joint Committee on Cancer Lower Gastrointestinal Tract Expert Panel and the Peritoneal Surface Malignancies Consortium. A.N.H. reports receiving grants from the National Institutes of Health, American Cancer Society, ACPMP Research Foundation, Dalton Family Foundation and Pfizer. A.N.H. also reports receiving consulting fees from MJH Life Sciences and Bayer outside the submitted work. M.J.O. and K.I.V. are Scientific Advisory Board members for the ACPMP Research Foundation. M.J.O. reports receiving research funding from Takeda, Roche, Lilly, Merck, Medimmune, Bristol\u2013Myers Squibb (BMS), Nouscom and Phanes. M.J.O. also reports consulting fees from Roche, Astellas, Medimmune, Merck, Amgen, Takeda, Janssen, Pfizer, Array, Gritstone, Simcere, Atreca and Bayer. K.I.V. reports receiving grants from the National Institutes of Health and ACPMP Research Foundation. K.I.V. also reports financial interests as the Chief Executive Officer and Founder of Applied Organoids. A.M.L. is a Medical Advisory Board member for the ACPMP Research Foundation and reports receiving grants from the Levine Family Chancellor\u2019s Endowed Chair in Surgical Oncology, National Institutes of Health, and Department of Defense, as well as generous gifts from the estate of Elisabeth and Ad Creemers, the Euske Family Foundation, the Gastrointestinal Cancer Research Fund and the Peritoneal Metastasis Research Fund at the University of California, San Diego. P.W. reports receiving grants from the Pittsburgh Foundation and the ACPMP Research Foundation. R.M.G. reports personal fees from Adaptimmune, AstraZeneca, Bayer, Compass Therapeutics, Focal Medical, G1 Therapeutics, Genentech, GlaxoSmithKline, Haystack Oncology, Innovative Cellular Therapeutics, Merck, Sorrento Therapeutics, Taiho Oncology, Takeda, Valar Technologies and Wolters Kluwer Health outside the submitted work. R.M.G. also reports owning stock options in Focal Medical, Haystack Oncology and Compass Therapeutics. D.B.J. has served on advisory boards or as a consultant for AstraZeneca, BMS, The Jackson Laboratory, Mallinckrodt, Merck, Mosaic ImmunoEngineering, Novartis, Pfizer, Targovax and Teiko; has received funding from BMS and Incyte; and has patents pending for the use of MHC-II as a biomarker for immune checkpoint inhibitor response and for abatacept as treatment for immune-related adverse events. A.S. has served on advisory boards for Merus, Guardant, Pfizer, Regeneron\/Sanofi and Catalyst Pharmaceuticals. A.S. also reports receiving funding (to the University of Chicago Medical Center)\u00a0from Hutchison MediPharma, Takeda, Merck, Verastem Oncology, Turning Point Therapeutics, Gritstone, Bolt Therapeutics, BMS, Pfizer, Astellas, Oncologie, Macogenics, Seattle Genetics, Amgen, Daiichi, Lilly, Jacobio, Astrazeneca, Jazz Pharma and Agenus. N.C.Z. reports receiving grants from the National Institutes of Health, Department of Defense, and Eli Lilly and Company. D.S. is a volunteer Executive Director and Board member for the ACPMP Research Foundation. W.C.F., C.E., M.K.W., M.H., K.I. and E.W. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}